SPORE in Brain Cancer

脑癌中的孢子

• 批准号: 7921427
• 负责人: W K ALFRED Yung
• 金额: $ 230万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7921427
• 关键词: SPORE; Brain; Cancer

The objective of The University of Texas M. D. Anderson Cancer Center (UTMDACC) SPORE in Brain Cancer is to develop a robust translational research program with an emphasis on innovative treatments based on combinations of agents, molecularly-based diagnosis, and therapy monitoring, through which significant impact on the care of patients with malignant brain tumors will be achieved. UTMDACC has established the elimination of brain tumors as a priority and has made significant investments in this goal through establishment of a Brain Tumor Center and a Multidisciplinary Research Program to support training and research across several departmental boundaries, including neuro-oncology, neuro-surgery, neuro-pathology, diagnostic imaging, radiation oncology, epidemiology, molecular therapeutics, molecular genetics, molecular biology, pediatrics, and statistics. With this support, we have successfully organized an efficient and productive infrastructure that forms the basis for this SPORE. The translational research in this application is based on recent insights into the molecular basis of brain tumors and aims to translate these findings into innovative approaches to improve molecular diagnosis so that patients receive the therapy most likely to be benefit them, permit early evaluation of response to targeted treatment, and establish new and effective treatments based on oncolytic viruses and small molecule signal transduction inhibitors. The focus of the four Projects is described below: Project 1: Test a targeted oncolytic adenovirus, Delta-24-RGD in the clinic, and improve it by combining it with temozolomide and by delivery with mesenchymal stem cells. Project 2: Test PI3K inhibitor PX-866 in the clinic and develop rational combination therapies based on it. Project 3: Develop a molecular biomarker panel capable of identifying patients not likely to benefit from standard therapy, test it in the RTOG-0525 clinical trial with over 800 patients, and identify novel targets in the treatment of resistant tumors to support new therapy development. Project 4: Explore genetic predictors of neurocognitive and clinical outcome in glioblastoma patients. Five Cores (Administrative, Pathology and Tissue Procurement, Biostatistics, Clinical and Animal) will support the Projects, Career Development Program, and Developmental Research Program. It is imperative that we aggressively undertake translational research, as is embodied in this proposal to develop more effective approaches for patients with brain cancer; there are no effective treatment approaches for this patient population, and this SPORE guarantees that all of the resources of the UTMDACC Brain Tumor Research Program, as well as the considerable resources of the entire institution, will be brought to bear on this important public health problem.

德克萨斯大学 M.D. 安德森癌症中心 (UTMDACC) SPORE 在脑癌方面的目标是开发一个强大的转化研究计划，重点是基于药物组合、分子诊断和治疗监测的创新治疗，通过该计划，显着对恶性脑肿瘤患者的护理将产生影响。 UTMDACC 将消除脑肿瘤作为优先事项，并通过建立脑肿瘤中心和多学科研究计划来支持跨多个部门的培训和研究，包括神经肿瘤学、神经外科、神经病理学、诊断成像、放射肿瘤学、流行病学、分子治疗、分子遗传学、分子生物学、儿科和统计学。有了这种支持，我们成功地组织了一个高效且富有成效的基础设施，构成了这个 SPORE 的基础。本申请中的转化研究基于对脑肿瘤分子基础的最新见解，旨在将这些发现转化为改进分子诊断的创新方法，以便患者接受最有可能使其受益的治疗，并允许早期评估对脑肿瘤的反应靶向治疗，建立基于溶瘤病毒和小分子信号转导抑制剂的新型有效治疗方法。四个项目的重点描述如下： 项目1：在临床测试靶向溶瘤腺病毒Delta-24-RGD，并通过将其与替莫唑胺结合以及与间充质干细胞一起递送来对其进行改进。 项目2：PI3K抑制剂PX-866的临床试验并基于其开发合理的联合疗法。 项目 3：开发一个分子生物标志物组，能够识别不太可能从标准治疗中受益的患者，在 RTOG-0525 临床试验中对 800 多名患者进行测试，并确定治疗耐药肿瘤的新靶点，以支持新疗法的开发。 项目 4：探索胶质母细胞瘤患者神经认知和临床结果的遗传预测因子。 五个核心（行政、病理学和组织采购、生物统计学、临床和动物）将支持这些项目、职业发展计划和发展研究计划。我们必须积极开展转化研究，正如该提案所体现的那样，为脑癌患者开发更有效的方法；对于这一患者群体，目前尚无有效的治疗方法，而该 SPORE 保证 UTMDACC 脑肿瘤研究计划的所有资源以及整个机构的大量资源将用于解决这一重要的公共卫生问题。